S
Spatial Genomics
Simultaneously assay single-cell gene expression, protein expression, and genomic and epigenomic states within intact cells and tissues
About Spatial Genomics
Spatial Genomics is a cutting-edge biotechnology startup that operates in the field of spatial genomics. The company's primary offering is the GenePS device, a highly sensitive confocal imager that enables detailed spatial research. This device, combined with advanced fluidics, delivers excellent results in the analysis of single-cell gene expression, protein expression, and genomic and epigenomic states within intact cells and tissues.
The company's target market includes researchers and scientists in the fields of fundamental biology, precision medicine, drug development, and diagnostics. Spatial Genomics' business model revolves around selling the GenePS device and providing off-the-shelf and custom gene panels to meet the specific project needs of its clients. Additionally, the company offers powerful analysis software to help clients quickly review the results of their research.
One of the key technologies developed by Spatial Genomics is sequential fluorescence in situ hybridization (seqFISH), an advanced biomolecular analysis method that combines imaging with combinatorial molecular barcoding. This technology allows the GenePS platform to generate multi-omic analyses beyond the capabilities of other types of spatial genomics systems.
In simpler terms, Spatial Genomics' technology allows scientists to see and understand the complex mixtures of cell types that make up tissues and organs. This is a significant advancement in the field of cell biology, as it allows for a more comprehensive understanding of cellular types, states, and interactions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Gold Coast, Australia
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 58.9/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Drug Development, Precision Medicine, Tech for Biotech and Pharma, Hard Tech, proteomics
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Feb 2022 | $56M | $224M | 12 West Capital · Fulgent Genetics | ↗ |
Growth signals
Latest recorded traffic for Spatial Genomics is 1.7K monthly website visits, up 70% over the last three months. Spatial Genomics's team declined 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Fulgent Genetics- 1C12 West Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Spatial Genomics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Spatial Genomics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







